Skip to content
AnalystLens

BOSTON SCIENTIFIC CORPBSX

Sector
Healthcare
Industry
Surgical & Medical Instruments & Apparatus
Exchange
NYSE

Stock Price $BSX

Latest filings

You are here#25 of 40 in Healthcare by market cap

Filing record · 2016–202610-K1310-Q328-K181

BSX filed 13 annual reports (10-K), 32 quarterly reports (10-Q) and 181 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’17Aug ’17
  2. Material agreement8-K · Nov ’19Nov ’19
  3. Leadership change8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

01—Key figures

Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  19. $20.07B
YoY changeLargest recent move+19.9%in FY21Latest +19.9%

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →
All BSX Financial Metrics59 metrics

Income Statement14

Balance Sheet26

Cash Flow15

Per Share4

02—Overview

BOSTON SCIENTIFIC CORP Financial Overview 2021–2025

Updated Jul 10, 2026

Boston Scientific's net income skyrocketed 56.4% to hit $2.898 billiona in FY2025, proving that its recent product launches can deliver massive operational leverage. This profitability surge underpins the central investment thesis: relentless strategic acquisitions and the runaway commercial adoption of the Farapulse Pulsed Field Ablation System are translating directly into outsized earnings power.

The medical device maker rapidly scaled its operations over a four-year window, with revenue growing from $11.888 billion in FY2021 to $20.074 billionb in FY2025. This top-line momentum accelerated further in Q1 2026, where net sales jumped another 11.6% to $5.203 billion and gross margins expanded to 69.4%. Capital deployment is matching this operational intensity. After completing the $3.7 billion buyout of Axonics in late 2024, the company is now navigating a $14.5 billion takeover of Penumbra. To balance this heavy acquisition spend, management authorized a new $5.0 billion stock repurchase program in early 2026 and instantly executed a $2 billion accelerated share repurchase, reversing its strategy after completely abstaining from buybacks in both FY2024 and FY2025.

The market has heavily premiumized this sustained growth trajectory. At the close of FY2025, the stock traded at $95.35c, commanding a steep 49.1x trailing earnings multiple based on its reported $1.94 in per-share earnings.

Recent Developments (Q4 2025 and Q1 2026)

Beyond top-line expansion, Boston Scientific's operational efficiency continues to accelerate. In Q1 2026, operating income climbed 19.5% year-over-year to $1.101 billiond. First-quarter net income surged 98.8% to $1.341 billion, aided by a discrete tax benefit.

The company is expanding its product pipeline through targeted investments outside its primary megadeals. In January 2026, it completed the $523 millione acquisition of Nalu Medical. In May 2026, the device maker deployed a $1.5 billion initial investment for a 33.75% equity stake in MiRus LLC, securing an exclusive $3.0 billion option to acquire its TAVR system. Bulls argue the stock is attractively priced, with its valuation compressing to 29.1x trailing earnings as of the Q1 2026 earnings date. Conversely, bears warn that financing multiple simultaneous multibillion-dollar acquisitions creates measurable balance sheet risk.

What to watch: clinical and regulatory milestones for the MiRus TAVR system; commercial impacts from the HI-PEITHO and CHAMPION-AF trial results.

03—Filings

Recent SEC Filings

  1. 8-KBOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Oct 7, 2026)Boston Scientific (BSX) filed an 8-K on October 7, 2026 disclosing two leadership changes and a structural reorganization. Joe Fitzgerald, currently EVP and Group President, Cardiovascular, will become EVP and Chief Operating Officer effective January 1, 2027, overseeing global operations, business units, and regions. His offer letter provides a $1,050,000 base salary, a 110% bonus target, and a 2027 equity award with a total grant-date fair value of $7,000,000, vesting 25% per year. Concurrently, the company will establish three reportable segments effective January 1, 2027: Interventional Therapies, Rhythm Solutions, and MedSurg. The company says the structure is designed to speed decision-making and support strategic capital allocation. On the finance side, Emily Woodworth (Collins) will step down as Chief Accounting Officer effective March 1, 2027, remaining in a finance transformation role. Mark Bickel, currently SVP, Finance and Global Controller of Cardiovascular, will succeed her as CAO on the same date. The filing states Woodworth's transition is not due to any disagreement on financial statements, internal controls, operations, policies, or practices, which is a standard but important disclosure for investors to note. For investors, the most significant items are the segment realignment, which will change how BSX reports results and may affect comparability with prior periods, and the continuity of senior operating leadership under Fitzgerald. The filing references the anticipated Penumbra acquisition as part of the Interventional Therapies segment, so its closing timing will also matter. Segment-level financial details and any reporting-change recasts are not included in this filing and should be reviewed in forthcoming disclosures.
  2. 8-KBOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Sep 23, 2026)Boston Scientific Corporation (BSX) has announced the upcoming retirement of Arthur C. Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027. This transition is a significant event for investors as Mr. Butcher has held a key leadership position within the company. While he will be stepping down from his operational role, he is expected to serve as a senior advisor until February 26, 2027, ensuring a smooth handover and continuity. This advisory role will provide him with a prorated base salary of $780,000.
  3. 8-KBOSTON SCIENTIFIC CORP 8-K Report, Cybersecurity Incident (Sep 8, 2026)Boston Scientific Corporation (BSX) has filed an 8-K detailing the ongoing impact of a significant cybersecurity incident first identified on August 25, 2026. The incident led to a global disruption of IT systems, affecting manufacturing, order processing, and shipping operations. While the Company has made substantial progress in restoring its distribution network and resuming manufacturing at most facilities, full operational recovery is still uncertain. Crucially, BSX now anticipates that this incident will materially impact its third-quarter and full-year 2026 financial results, likely causing the company to miss previously issued net sales growth and adjusted EPS guidance. The company expects to provide a more detailed financial outlook update during its Q3 2026 earnings call in late October. Despite the near-term financial headwinds, BSX currently does not expect the incident to materially affect its long-term financial condition. The investigation into the incident is ongoing, and the company is working with third-party experts to assess and contain the impact. Investors should note that the full extent of revenue recovery and the ultimate financial impact are still being determined. BSX has also highlighted various risks, including potential litigation, reputational damage, and further operational disruptions, that could arise from this cybersecurity event.
  4. 8-KBOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Aug 26, 2026)Boston Scientific Corporation (BSX) has disclosed a significant cybersecurity incident that occurred on August 25, 2026. This incident has led to a global disruption of the Company's operations, impacting information technology systems and business applications. Notably, the disruption affects the ability to process and ship customer orders, indicating a direct impact on revenue generation and supply chain continuity. The Company has initiated its incident response protocols and is working with third-party experts to investigate, assess, and contain the threat. While efforts are underway to restore affected systems, the timeline for full recovery remains uncertain. At this time, the full scope, nature, and financial implications of the incident are unknown, and Boston Scientific has not yet determined if it will have a material impact on the company's financial condition or results of operations.
  5. 8-KBOSTON SCIENTIFIC CORP 8-K Report, Financial Results (Jul 29, 2026)Boston Scientific (BSX) reported second-quarter 2026 net sales of $5.442 billion, up 7.5% on a reported basis and 7.0% on an operational and organic basis versus the prior year. Growth was driven by Cardiovascular (up 8.3% reported, 7.8% organic) and MedSurg (up 5.9% reported, 5.4% organic). Regionally, Latin America and Canada (up 22.4% reported, 16.2% operational) and Asia-Pacific (up 11.2%) led, while the U.S. grew 6.2% and EMEA 4.2% on an operational basis. Adjusted EPS of $0.86 beat the company's $0.82 to $0.84 guidance range, and GAAP diluted EPS was $0.61 versus $0.53 a year ago. GAAP results were affected by a $76 million litigation-related charge and adjustments for IEEPA tariff refunds and deferred tax items. The company lowered its full-year 2026 outlook to reported net sales growth of 5.5% to 6.5% (5% to 6% organic) and adjusted EPS of $3.28 to $3.32. Third-quarter guidance calls for 3% to 5% sales growth and adjusted EPS of $0.80 to $0.82. Management described the environment as dynamic and emphasized prioritizing investments in its highest-impact opportunities. Capital allocation included completing a $2 billion accelerated share repurchase (about 40 million shares retired) and a $1.5 billion investment in MiRus LLC for roughly a 34% equity stake and an exclusive option to acquire its TAVR business. Clinical and pipeline news was active, including FRACTURE IDE trial data for the SEISMIQ coronary lithotripsy catheter, AVANT GUARD data supporting FARAPULSE in first-line persistent AF, and enrollment start in the pivotal FARADIGM trial for the FARAFLEX mapping and PFA catheter. Several of these products remain investigational and are not yet available for sale. Investors will likely focus on whether the reduced full-year guidance reflects softness in the second half and on the durability of growth in the core electrophysiology and cardiovascular franchises.
View all 8-K filings →
View all filings (10-K, 10-Q, 8-K, proxy & more) →

04—See also

Related Companies

Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.